Effect of tolcapone on the haemodynamic effects and tolerability of desipramine.

Author(s): Jorga KM, Fotteler B, Modi M, Rabbia M

Affiliation(s): Department of Research and Development, F. Hoffmann-La Roche Ltd., Basel, Switzerland. karin.jorga@roche.com

Publication date & source: 2000, Eur Neurol., 44(2):94-103.

Publication type: Clinical Trial; Randomized Controlled Trial

Background and Purpose: To determine the changes in haemodynamics, tolerability and pharmacokinetics that may occur when a combination of tolcapone and levodopa/carbidopa are given with desipramine. Methods: In a crossover study, 22 healthy subjects received desipramine during two 13-day treatment periods (25 mg t.i.d. for 3 days and 50 mg t.i.d. for 10 days), with a washout period of 10-15 days. Subjects received levodopa/carbidopa (100 mg/25 mg t.i.d. for 5 days, days 9-13) and concomitant, double-blind, randomized treatment with either tolcapone (200 mg t.i.d.) or placebo. Results: No significant pharmacodynamic and pharmacokinetic interactions occurred between tolcapone and desipramine. Adverse events were predictable based on the known effects of the individual drugs. Conclusions: Tolcapone can be combined with levodopa/carbidopa and desipramine in patients with Parkinson's disease. Copyright 2000 S. Karger AG, Basel